Sensorion

Stocks

ALSEN

FR0012596468

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-08-07 EDT			5-day change	1st Jan Change
0.2890 ^EUR	+1.58%		+1.76%	-14.24%

06-11	Sensorion continues its decline despite Stifel's positive outlook
06-10	Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate	CI

Sensorion selects SENS-601 as lead program

The clinical-stage biotechnology company dedicated to developing novel therapies to restore, treat, and prevent hearing loss disorders has selected SENS-601, targeting GJB2 gene-related hearing loss, as its lead program.

Jean-Yves Courtial

Published on 06/10/2026 at 03:01 am EDT

MarketScreener.com - Translated by Marketscreener - See original

Add MarketScreener to your sources

SENSORION

+1.58%

Sensorion selects SENS-601 as lead program

The company has filed Clinical Trial Applications in Canada and France to evaluate the safety, tolerance, and efficacy of intra-cochlear administration of SENS-601 for the treatment of GJB2 gene-mediated hearing loss in pediatric patients.

In parallel, Sensorion has decided to discontinue the clinical development of SENS-501 for OTOF gene-related hearing loss following a strategic review of its drug candidate portfolio, and is consequently terminating recruitment for the Audiogene trial.

Add MarketScreener to your sources

Latest news about Sensorion

06-11	Sensorion continues its decline despite Stifel's positive outlook
06-10	Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate	CI
06-10	Sensorion selects SENS-601 as lead program
06-10	Sensorion Applies for Clinical Trial in Canada, France for SENS-601	MT
05-18	French Biotech Company Sensorion Names New CEO	MT
05-18	Fred Chereau appointed CEO of Sensorion
05-18	Sensorion SA Announces Chief Executive Officer Changes	CI
05-18	Sensorion SA Announces Resignation of Géraldine Honnet as Chief Medical Officer	CI
04-30	Certain Ordinary Shares of Sensorion SA are subject to a Lock-Up Agreement Ending on 1-MAY-2026.	CI
03-23	Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development	CI
03-23	Stocks to watch today
03-23	Sensorion unveils six-month data from clinical trial
03-18	Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	Sensorion Announces CEO Transition	CI
02-17	Sensorion Sa Announces Stepping Down of Nawal Ouzren as Director on the Board	CI

Chart Sensorion

Duration

Period

ALSEN: Dynamic Chart

Company Profile

Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-15 Significant Split/Dividend

More about the company